Analysts Set Axon Enterprise, Inc. (NASDAQ:AXON) PT at $335.27

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $335.27.

Several brokerages have commented on AXON. JMP Securities restated a “market outperform” rating and set a $375.00 target price on shares of Axon Enterprise in a research report on Tuesday, May 7th. JPMorgan Chase & Co. boosted their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research report on Thursday, April 11th. TheStreet lowered shares of Axon Enterprise from a “b” rating to a “c+” rating in a research report on Tuesday, February 27th. Morgan Stanley upped their target price on shares of Axon Enterprise from $285.00 to $310.00 and gave the company an “equal weight” rating in a report on Friday, April 26th. Finally, The Goldman Sachs Group upped their target price on shares of Axon Enterprise from $297.00 to $339.00 and gave the company a “buy” rating in a report on Wednesday, February 28th.

Axon Enterprise Stock Down 1.1 %

Shares of Axon Enterprise stock opened at $284.87 on Monday. Axon Enterprise has a 52-week low of $175.37 and a 52-week high of $329.87. The company has a 50 day moving average of $307.19 and a 200 day moving average of $273.52. The company has a quick ratio of 2.55, a current ratio of 2.91 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $21.50 billion, a P/E ratio of 83.30 and a beta of 0.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.20. The company had revenue of $460.74 million for the quarter, compared to analysts’ expectations of $441.57 million. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The firm’s revenue for the quarter was up 34.3% on a year-over-year basis. During the same quarter last year, the company earned $0.51 earnings per share. As a group, research analysts forecast that Axon Enterprise will post 2.35 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In other news, Director Jeri Williams sold 308 shares of Axon Enterprise stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the sale, the director now owns 1,607 shares of the company’s stock, valued at approximately $498,282.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Jeri Williams sold 308 shares of the company’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $310.07, for a total value of $95,501.56. Following the completion of the sale, the director now owns 1,607 shares in the company, valued at $498,282.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua Isner sold 44,000 shares of the business’s stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $309.96, for a total value of $13,638,240.00. Following the completion of the transaction, the president now directly owns 275,843 shares of the company’s stock, valued at $85,500,296.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 87,976 shares of company stock valued at $27,268,201. Corporate insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ING Groep NV raised its stake in Axon Enterprise by 9.3% during the 4th quarter. ING Groep NV now owns 9,643 shares of the biotechnology company’s stock worth $2,491,000 after buying an additional 821 shares during the period. Westfield Capital Management Co. LP raised its position in Axon Enterprise by 184.3% during the third quarter. Westfield Capital Management Co. LP now owns 696,193 shares of the biotechnology company’s stock valued at $138,535,000 after purchasing an additional 451,350 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its stake in shares of Axon Enterprise by 18.4% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 104,587 shares of the biotechnology company’s stock valued at $27,019,000 after buying an additional 16,230 shares during the last quarter. BKM Wealth Management LLC bought a new position in shares of Axon Enterprise during the fourth quarter valued at about $32,000. Finally, Apollon Wealth Management LLC bought a new stake in shares of Axon Enterprise in the fourth quarter worth about $234,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.